Sirtuin 1 and endothelial glycocalyx

Mark Lipphardt1,2 · Jong Wook Song1,3 · Michael S Goligorsky1

Abstract
Sirtuin1 deficiency or reduced activity comprises one of the hallmarks of diseases as diverse as chronic cardiovascular, renal, and metabolic, some malignancies, and infections, as well as aging-associated diseases. In a mouse model of endothelium-limited defect in sirtuin 1 deacetylase activity, we found a dramatic reduction in the volume of endothelial glycocalyx. This was associated with the surge in the levels of one of key scaffolding heparan sulfate proteoglycans of endothelial glycocalyx, syndecan-4, and specifically, its extracellular domain (ectodomain). We found that the defect in endothelial sirtuin 1 deacetylase activity is associated with (a) elevated basal and stimulated levels of superoxide generation (via the FoxO1 over-acetylation mechanism) and (b) increased nuclear translocation of NF-kB (via p65 over-acetylation mechanism). These findings laid the foundation for the proposed novel function of sirtuin 1, namely, the maintenance of endothelial glycocalyx, particularly manifest in conditions associated with sirtuin 1 depletion. In the forthcoming review, we summarize the emerging conceptual framework of the enhanced glycocalyx degradation in the states of defective endothelial sirtuin 1 function, thus explaining a broad footprint of the syndrome of endothelial dysfunction, from impaired flow-induced nitric oxide production, deterrent leukocytes infiltration, increased endothelial permeability, coagulation, and pro-inflammatory changes to development of microvascular rarefaction and progression of an underlying disease.

Keywords Glycocalyx · Sirtuin 1 · Syndecan-4 · Sheddases · NF-kB · Oxidative stress

Introduction
Sirtuin family (SIRT) of protein and histone deacetylases is represented by seven mammalian SIRT proteins (SIRT1-SIRT7). Sirtuins have been the subject of multitude of investigations which have demonstrated that SIRT proteins are responsible for diverse cell functions and are capable of protection against several diseases like diabetes, cancer, or cardiovascular diseases [50, 53, 63]. There are approximately 500 different known target proteins for SIRT-deacetylation. SIRT1, the founding member of the family [39], is an NAD-dependent deacetylase participating in chromatin regulation (by deacetylating H3K9, H3K56, H4K16, H1K26, SUV39H1, p300, and PCAF); DNA repair (HDAC1, PARP1, p53, Ku70, NBS1, E2F1, RB, XPA, WRN, survivin, β-catenin, MYC, NF-κB, and TOPBP1), and cell metabolism (PGC1α, FOXO1, FOXO3A, FOXA2, CRCT1, CRCT2, PPARα, PPARγ, LXR, FXR, RARβ, SREBP1C, SREBP2, HNF4α, HIF1α, HIF2α, CREB, NKX2–1, STAT3, TFAM, MYOD, NHLH2, UCP2, TSC2, eNOS, LKB1, SMAD7, AKT, ATG5, ATG7, ATG8, 14-3-3ζ, PGAM1, A1CDS1, PTP1B, and S6K1) [17]. Studies of the role of SIRT1 in endothelial cells were significantly accelerated by the creation of SIRT1endo−/− mice [97] which demonstrated that this deacetylase participates in angiogenesis.

We have recreated and further explored this mouse model [22, 76, 123] to demonstrate development of premature senescence of endothelial cells, rarefaction of renal peritubular microvascular network, diastolic dysfunction, reduced expression of the membrane-tethered matrix metalloproteinase MMP-14, defective acetylcholine-induced vasorelaxation, and propensity toward tubulointerstitial fibrosis—all hallmarks of developing endothelial cell dysfunction. The fact that dysfunctional endothelial cells can trigger fibrosis alluded
to the possibility of secretory products of such cells inducing fibroblast activation and prompted us to perform an unbiased proteomic screen of the secretome of SIRT1-deficient vis-à-vis control endothelial cells isolated from renal microvasculature [70–72]. Among various differentially expressed proteins in the aberrant secretome, syndecan-4 ectodomain was prominently present [73]. Syndecan-4 is a major proteoglycan of endothelial cell glyocalyx. Hence, in parallel studies of SIRT1endo−/− mice, Song et al. [110] demonstrated by dual-fluorophore dilution technique that endothelial glyocalyx of these mice is disintegrated. Based on these findings, we deduced that SIRT1 may have another, yet unidentified, function in maintaining endothelial glyocalyx integrity. This review summarizes our and others’ most recent findings on this subject. It should be noted that this review is not intended to illustrate the entire spectrum of glyocalyx components and functions, rather it is limited to exhibit our hypothesis that SIRT1-induced deacetylation is crucial for the maintenance of endothelial glyocalyx.

**Endothelial glyocalyx**

The endothelial glyocalyx (EG) can be defined as a layer with a high amount of carbohydrates which covers the vascular endothelium. It is coated with a carbohydrate-rich layer of an average thickness of 0.2–2 μm and consisting of hyaluronic acid (HA) cords reaching 1 μm in length, heparan sulfate (HS) chains reaching in length 200 nm, and comprising 50–90% of endothelial glycosaminoglycans, with an admixture of dermatan, keratan, and chondroitin sulfates [103]. The high degree of sulfation of these components provides EG with a net negative charge [103]. Among those mentioned glycosaminoglycans, the most common ones are HS followed by chondroitin sulfate and HA, although the levels of each glycosaminoglycan depend highly on various current stimuli [99]. HA differs from the other glycosaminoglycans, since it has no linkage to a core protein and it binds to the osteopontin receptor CD44 [87]. With the newest technique, the use of super-resolution optical microscopy (STORM), the study group of Fan et al. was able to visualize HA as long molecules forming a hexagonal network which covers the endothelial lumen. HS, on the other hand, was visualized as a shorter molecule with a straight positioning to the cell surface [37]. The HA network plays a major role in the stability and function of the EG, as passage through the EG is regulated by HA [126]. Moreover, endothelial mechanosensing and the preservation of endothelial quiescence are in need of the presence of HA [98]. HS acts mainly as a mechanosensor arbitrating the regular release of NO as shown by Florian et al. [38].

The membrane-tethered scaffold for these glycosaminoglycans consists of two families of proteoglycans: syndecans 1–4 (single membrane-spanning domain) and glypicans 1–6 (glycosylphosphatidylinositol-anchored) [103]. Since there are multiple ways of modifications of the glycosaminoglycan chains, the diversity of the glycosaminoglycans results in the alternation of specific protein binding, in the alternation of protein functions, and in the modulation of vascular permeability [103]. Consequently, the EG creates a dynamic balance between itself and the luminal components, alternating its composition and thickness [103].

In addition, several glycoprotein families (selectins, integrins, and immunoglobulins) are present in EG. Their main role of action is the regulation of cell recruitment from the bloodstream. Selectins present in EG are E-selectin and P-selectin with their main action in the field of cell interaction between leukocytes and the endothelium [111]. Especially E-selectin is overexpressed in endothelial cells after stimulation by cytokines [57]. Integrins can be described as molecules composed of non-covalently bound α and β subunits [103]. Luminally endothelial cells express integrin αVβ3, mediating the cell interaction between the endothelial cell and platelets [9]. The other integrins expressed at EG are associated with binding to the basement membrane and interact with laminin, fibronectin, and collagen [103]. The immunoglobulins are divided in a cytoplasmic, a transmembrane, and an extracellular part, acting as ligands for integrins and mediate leukocyte homing to the endothelium [103].

EG provides a repository for diverse biologically active molecules, as it incorporates and interacts with extracellular superoxide dismutase (SOD), xanthine oxidoreductase, interleukins, like IL2, IL5, IL7, IL8, and IL12, low density lipoprotein (LDL) and LDL lipase, bFGF, VEGF, and TGF-beta, and several regulators of coagulation, like antithrombin III, heparin cofactor II, and tissue pathway factor inhibitor [103]. EG is a guardian of endothelial cell homeostatic functions. Due to its unique location, this structure provides a passive barrier to water and solutes (regulation of vascular permeability), and to the interaction between circulating cells and the endothelial cells (regulation of leukocyte trafficking) [5]. It also serves as a sensor of mechanical forces, such as shear stress and pressure, and shields cell surface receptors preventing their hyper-activation [5, 40].

This structure is, however, quite vulnerable and tends to disintegrate under the influence of various stressors, such as endotoxins, ischemia/hypoxia/reperfusion, oxidative stress, among others [107]. It also leads to hyper-activation of plasma membrane receptors left exposed to respective unhindered ligands, with further activation of endothelial cells and propagation of danger signaling [27]. The degradation of EG is also accompanied by the compromised anti-coagulant properties of this layer, increased endothelial permeability, reduced antioxidant barrier, enhanced transmigration of pro-inflammatory cells, impaired mechanotransduction, and endothelial nitric oxide synthase activity [2, 27, 107]. In acute kidney injury induced by ischemia/reperfusion, sepsis, and/
or kidney transplantation, EG is impaired both in experimental animals and in humans [19, 47, 84, 95, 108, 109, 134].

Another condition frequently associated with the degradation of EG is diabetic nephropathy. Deckert and colleagues [25] were the first to show that the de novo synthesis of heparan sulfate was reduced in fibroblasts isolated from diabetes patients with albuminuria, but not from those without albuminuria or control healthy subjects, and formulated a hypothesis that the loss of EG is a prerequisite for the developing diabetic nephropathy. Recently, upregulation of endothelin-1 in diabetes was incriminated in the induction of heparanase in podocytes, resulting in impairment of glomerular EG [43].

This is in agreement with studies by different investigators who have demonstrated the loss of glycocalyx integrity in diabetes mellitus [85, 90, 91]. Considering the role of EG in endothelial cell function and dysfunction [133], its putative dependence on SIRT1 expression and activity, both impaired in the above pathologic conditions, gains additional import. Our recent unbiased proteomic studies of microvascular endothelial cells expressing deacetylation-deficient SIRT1 have revealed upregulation of syndecan-4, and, specifically, its ectodomain. Scenarios tentatively explaining this finding are briefly summarized below.

**NF-κB as a target for SIRT1 deacetylation**

It has been well-documented that SIRT1 is a negative regulator of inflammation, in part due to its effects on nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), one of the target proteins for SIRT1-deacetylation [130]. In mammals, the following members of the NF-κB family have been described: NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB, and c-Rel [10, 45]. NF-κB is known for its regulatory effects on transcription of DNA, cytokine production, and cell survival [13]. NF-κB usually forms dimers, which is necessary for binding DNA. One typical structure of NF-κB is the p50-p65 dimer (NF-κB1/RelA) [20].

In order to unfold its transcriptional activity, NF-κB needs to translocate into the nucleus. In an inactive state NF-κB remains in the cytoplasm and is bound to specific inhibitors, the Iκ-B proteins (IκBa, IκBb and IκBg), which, in turn, bind to the Rel homology domain (RHD) of NF-κB and therefore interfere with its nuclear translocation [10, 121]. Hence the activation of NF-κB is linked to the release of its inhibitors. Pro-inflammatory cytokines induce the activation of the IκB kinase complex, releasing NF-κB from its inhibitors and consequently leading to NF-κB nuclear translocation [10, 121].

NF-κB is a target protein for SIRT1-deacetylation (Fig. 1). In fact, SIRT1 binds to p65 protein disabling its transcriptional activity by deacetylating p65 at Lys310 [12, 131]. Consistent with this, induction of SIRT1 results in the inhibition of NF-κB-dependent inflammatory pathway [93, 131] and vice versa, which reduced activation of SIRT1 that leads to enhanced NF-κB signaling [58].

This relation between SIRT1 and NF-κB becomes a main concern when SIRT1 is inhibited exclusively in the endothelium, which has been demonstrated to represent an excellent model of global endothelial dysfunction [123]. In case of SIRT1 inhibition in endothelial cells, the increased NF-κB signaling could lead to the enhanced degradation of the EG in part due to induced shedding of EG proteoglycans and activation of heparanases.

**Syndecan-4: a proteoglycan of the endothelial glycocalyx**

Proteoglycans represent one of the essential components of the EG, which is also true for the underlying basement membrane of endothelial cells [125]. Among those proteoglycans there is the family of syndecans. Syndecans are transmembrane receptors with autonomous and combined signal capacity which have mostly heparan sulfate glycosaminoglycans covalently bound to their extracellular domain [23, 24, 36]. The family of syndecans includes four members: syndecans1–4. Syndecan-1 is typically found in epithelial, endothelial, and plasma cells, whereas syndecan-2 is rich in endothelial and mesenchymal cells and syndecan-3 is mostly found in neural crest-derived cells [64, 118]. Syndecan-4, however, is the only family member with a ubiquitous distribution and is highly expressed in endothelial and epithelial cells in the kidney and other organs [125]. In cultured endothelial cells, inflammatory mediators such as lipopolysaccharide (LPS) and interleukin 1β (IL-1β) syndecan-4 expression showed a rapid increase, while Syndecan-1 and -2 expression decreased and syndecan-3 was unaffected [125] implying that this proteoglycan may represent a key proinflammatory sensor of endothelial cells. Syndecan-4 is a target of TNF-alpha-induced matrix metalloproteinase-9 leading to degradation of glycocalyx [101]. Syndecan-4 has been found to counteract effects of eNOS and serve as an enhancer of angiopoitin-2 secretion leading to antiangiogenesis [56]. The spectrum of Syndecan-4 signaling properties has been comprehensively reviewed [34]:

One of the main functions of syndecan-4 is to serve as a coreceptor for heparin-binding growth factors, such as fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), and platelet-derived growth factors (PDGFs), coordinating the extracellular space distribution of these growth factors [119].

In order to understand the signaling properties and the array of functions of syndecan-4, it is necessary to look separately at the different domains of this molecule: the transmembrane, the transmembrane, and the intracellular. The cleavage and shedding of the syndecan-4 extracellular domain, also termed
ectodomain, play an important role in mediation of its extracellular signaling. The shed syndecan-4 ectodomain regulates cellular adhesion to the surrounding matrix and is capable of orchestrating the direct contact of cells with ECM proteins [34, 122]. Shedding of this domain leads to the dissipation of extracellular SOD, heparin-binding growth factors, and a host of other biologically active substances mentioned above, which are concentrated within EG. The loss of their surface gradient compromises cellular defense against oxidative stress, reduces growth and pro-survival signaling, and impairs interactions with other cells [34].

At the transmembrane site, syndecan-4 unfolds three signaling functions: it non-covalently clusters into sodium dodecyl sulfate (SDS)-resistant oligomers (the hallmark of lipid-rich domains, such as caveolae) which harbor diverse signaling cascades; it balances the interaction between growth factors, their cognate receptors, and other cell membrane receptors; and it serves as a direct link between the ECM and intracellular signaling proteins [34].

Intracellular domain of syndecan-4 and one of its major binding partners, synectin, facilitates the binding of Rho guanidine dissociation inhibitor 1 (RhoGDI1) and serves to insulate and decrease the activity of Rho family GTPases that are incorporated into the syndecan-4–synectin–RhoGDI1 complex at the cell membrane [33] in the absence of growth factor stimulation. Upon stimulation by growth factors, syndecan-4 reverses the described decrease in the activity of Rho family GTPases through its ability to bind and activate PKCα. PKCα in turn phosphorylates RhoGDI1 at Ser96, which allows the release of sequestered RhoG and Rac1 [34].

The role of proteoglycans and one of their major members, syndecan-4, in a variety of pathologic processes, has been a subject of a score of investigations. After skin injury, the expression of syndecan-4, on the one hand, is temporarily decreased in those keratinocytes, which migrate into the wound, and, on the other hand, it is increased in those keratinocytes, which proliferate at the wound margins, with specific increase in fibroblasts within the forming granulation tissue [32, 41]. Mice with a disrupted syndecan-4 gene have delayed healing of skin wounds and impaired angiogenesis in the granulation tissue [28]. Furthermore, it has been shown that syndecan-4−/− mice have an increased mortality rate after a myocardial infarction due to cardiac rupture. Those cardiac events are associated with reduced inflammatory reaction and impaired granulation tissue formation due to reduced numbers of infiltrating leukocytes, fibroblasts, myofibroblasts, macrophages, and capillary vessels [80]. In addition, mice deficient in syndecan-4 have an increased susceptibility to LPS-injections manifested in increased mortality [55]. On this background, it has recently been reported that syndecan-4 knockout in mice protects against tubulointerstitial fibrosis apparently due to the reduction of tissue transglutaminase activity [106]. This finding has been substantiated by the study of Wee et al. showing the activation of transglutaminase 2 and syndecan-4 by tissue-resident natural killer cells in a model of aristolochic acid-induced nephropathy [129].
with a wealth of the abovementioned critical functions of syndecan-4, the question of the mechanism responsible for its reported pro-fibrotic action in renal injury requires elucidation.

It has been argued that these harmful effects could be due, at least in part, to the effects of its extracellular ectodomain [115], rather than the effects of the whole syndecan-4 molecule. In fact, the mouse knockout model of syndecan-4 deficiency has been generated by deleting the exon encoding the extracellular domain [106]. The physiology of the syndecan-4 ectodomain is noteworthy because it is highly distinct from functions of the whole molecule, as mentioned previously. The ectodomain of syndecan-4 promotes collagen cross-linking and induces innate immunity signaling, stimulates immune cell infiltration, therefore exhibiting a central role in chemotaxis [114]. The release of the ectodomain is induced by pro-inflammatory stimuli, like, for instance, in the event of tissue injury [74, 114]. On the other hand, maintenance mechanisms exist to prevent the excessive release of the ectodomain. One important maintaining factor is endothelial SIRT1.

SIRT1 exhibits an important functional role in maintaining homeostasis of endothelial cells, and in reverse, SIRT1 deficiency in endothelial cells leads to a long list of endothelial abnormalities, as mentioned above. One of these abnormalities is the loss of EG. The expression of the EG is dramatically reduced in SIRT1<sup>endo</sup>-/- mice, a model of global endothelial dysfunction [73, 123]. In addition, syndecan-4 ectodomain is highly upregulated in this model of global endothelial dysfunction. In other words, the impairment of EG goes hand in hand with an impaired whole syndecan-4 molecule, leading to an increased amount of shed syndecan-4, allowing the syndecan-4 ectodomain to be released and to participate in fibrogenesis. How does this occur?

Interestingly, syndecan-4 is a NF-κB target gene [115]. As described above, SIRT1 deacetylates p65 protein preventing the nucleus translocation of NF-κB [12, 131]. Hence, increased SIRT-1 activity results in the inhibition of NF-κB-dependent inflammatory reactions [93, 131] while the decreased SIRT-1 activity enhances NF-κB signaling [58]. Indeed, our studies showed that the nuclear translocation of NF-κB is increased and syndecan-4 transcripts are elevated in SIRT1<sup>endo</sup>-/- mice, whereas the expression of syndecan-4 on the surface of renal microvascular endothelial cells isolated from SIRT1<sup>endo</sup>-/- mice was found to be decreased in parallel with increased syndecan-4 ectodomain abundance in the secretome of these cells and in the interstitium of the kidneys undergoing fibrotic transformation after an experimental insult [73]. Apparently, despite the elevated message level, syndecan-4 ectodomain is shed from the endothelial surface of SIRT1<sup>endo</sup>-/- mice, thus depleting the major scaffolding component of EG. These relations between SIRT-1 and NF-κB may explain the degradation of the EG in SIRT1<sup>endo</sup>-/- mice, resulting in a higher amount of shedding of syndecan-4 (Fig. 2).

In addition to that, we have observed that renal microvascular endothelial cells isolated from SIRT1<sup>endo</sup>-/- mice have an increased basal and stimulated superoxide generation. This finding is consistent with the known effect of SIRT1 to deacetylate Forkhead box O (FoxO1) DNA-binding proteins. The deacetylated form is necessary for the post-translational modification of this transcription factor which is needed for its active modification and higher cellular defense against oxidative stress [15, 83]. In turn, increased oxidative stress in renal microvascular endothelial cells of SIRT1<sup>endo</sup>-/- mice further leads to the activation of a redox-sensitive domain of the sheddase cleaving the ectodomain of syndecan-4, disintegrin, and metalloproteinase domain-containing protein 17 (ADAM-17) [128]. Activation of ADAM-17 may be ultimately responsible for shedding of syndecan-4 [60].

**Sheddases targeting the endothelial glycocalyx**

Increased shedding of the EG components has been linked to the pathogenesis of a wide variety of diseases. There is data demonstrating the degradation of the EG in the course of hypertensive diseases or in the hemolytic uremic syndrome, as judged by the detection of increased amounts of shed heparan sulfates, syndecans, and hyaluronan into the bloodstream or the urine [8]. In a cohort study, it has been shown that trauma patients demonstrated a higher amount of shed EG components (syndecan-1, hyaluronic acid). The higher amount of shedding has been linked to a lower plasma colloid osmotic pressure, indicating a correlation between low plasma colloid osmotic pressure and degradation of the EG [100]. A different study with a similar approach disclosed the correlation between an increased release of atrial natriuretic peptide and higher plasma levels of EG components (hyaluronan, heparan sulfate, and syndecan-1) during hypervolemia [18]. There is also a hypothesis that the degradation of the EG manifests as an important step in the pathogenesis of malaria. Hempel et al. proposed that infected erythrocytes bind to the outer layer of the EG leading to increased shedding and allowing the parasites to interact with proteins in the deeper layer of the EG [51].

Shedding of the EG also causes biologically active components and proteins bound to the endothelial surface layer to disappear from the close vicinity of the luminal vascular surface, with the consequent loss of their respective local actions and gain of systemic cytokine-like effects [6]. For example, the loss of xanthine oxidoreductase at the endothelial surface leads to decreased production of uric acid [4], less lipoprotein lipase limits the activity of the lipid metabolism which further limits the number of chylomicrons, and free fatty acids to
parenchymal cells [62, 105]. Shedding of syndecan-4, as described in detail previously, provides a good example for the acquisition by the ectodomain of systemic effects.

Investigations of the shedding of the EG have been the target of a score of studies, and the results of these studies suggest that matrix metalloproteinases (MMPs) are the major contributors to cleaving scaffolding molecular components of the EG and, therefore, facilitating shedding under pathological circumstances [69]. MMPs are calcium-dependent zinc-containing endopeptidases that play an important role in tissue remodeling associated with morphogenesis, angiogenesis, wound healing, arthritis, and cancer [112, 124]. Once activated, MMPs degrade extracellular matrices (collagen, elastin, gelatin), induce cell migration by providing directional cues, create substrate-cleavage fragments, coordinate tissue architecture, and modify the activity of signaling molecules [113]. Specifically, MMP-2, MMP-7, and MMP-9 are capable of directly cleaving chondroitin sulfate [49] and MMP-1 cleaves the heparan sulfate proteoglycan syndecan-1 [35]. MMP-9 is also the major sheddase of syndecan-4 in glomerular endothelial cells in the setting of diabetic nephropathy [102]. Most importantly, both the active and proactive forms of MMP-2 and MMP-9 are stored in the vesicular compartment within endothelial cells, suggesting the existence of mechanisms by which MMPs can be rapidly released by these cells [117].

An additional important contributor to shedding of the EG is heparanase. Heparanase cleaves the glycosidic bond within the heparan sulfate chain at specific sites. It is synthesized as a pre-proheparanase, processed to proheparanase at the endoplasmic reticulum, and transported to the Golgi apparatus, where it is packaged into vesicles and finally secreted [46]. After secretion, heparanase interacts with cell membrane heparan sulfate proteoglycans (especially with syndecans), low density lipoprotein receptor-related proteins, and mannose 6-phosphate receptors [44]. Heparanase is involved in pathologic processes in tumor growth, angiogenesis, metastasis, inflammation, and glomerular diseases [88]. During the investigation of inflammatory settings, like vascular damage or rheumatoid arthritis, it has been discovered that heparanase expression occurs mainly in the epithelial and/or endothelial compartment [3, 46, 68] and is induced by inflammatory cytokines [21, 29, 61, 66, 107]. Its main mechanisms during inflammation is a result of neutrophil recruitment and the modulation of proinflammatory macrophage action. The induction of heparanase by inflammatory cytokines leads to the loss of the EG and therefore to endothelial hyperpermeability resulting in a higher amount of extravasation of neutrophils [104, 107]. However, there are also reports of high levels of heparanase resulting in a decreased amount of extravasation of neutrophils [67, 104]. Increased levels of heparanase also result in a decreased level of cell-surface heparan sulfate, making the toll-like receptor more accessible and
therefore increasing the activation of macrophages [16, 66]. The enzymatic activity of heparanase is well studied in multiple myeloma. Patients suffering from multiple myeloma were found to have an increased level of heparanase in the bone marrow plasma [61, 86], and over 90% of multiple myeloma patients had increased heparanase expression in gene array analysis [75].

Notably, during the progression of chronic kidney disease, heparanase exerts an important contributing role through its participation in renal fibrogenesis via controlling the epithelial-mesenchymal transition in renal tubular cells [79]. A recent study performed by Masola et al. showed protection against chronic kidney dysfunction by inhibiting heparanase [77]. Abassi et al. showed in their experiments more profound renal injuries in the ischemic reperfusion model in heparanase-overexpressing (Hpa-tg) mice [1]. They also demonstrated a higher number of biomarkers of epithelial mesenchymal transition in Hpa-tg mice, suggesting heparanase to be of importance in the process of kidney fibrosis. An assumption which the same group corroborated in a study shows high levels of epithelial-mesenchymal transition markers in wild-type mice, but no significant increase in those markers in heparanase-silenced tubular cells of the kidney [78]. As heparanase is also involved in the development of acute experimental glomerulonephritis via reinforcing renal leukocyte and macrophage influx by shrinking the heparan sulfate expression at the glomerulus [42], it is a great target for further clinical investigation.

Another type of sheddase is hyaluronidase. Hyaluronidase cleaves hyaluronan, a high-molecular weight, unsulfated glycosaminoglycan which is highly enriched on the apical surface of endothelial cells [30, 52]. It has been shown that there is an association between an increased hyaluronan metabolism and structural changes of the arterial wall with accelerated atherogenesis in type 1 diabetes as a result of heightened activity of hyaluronidase [89]. Furthermore, hyaluronidase has been implicated as a marker for various cancers, such as genitourinary, colorectal, or breast cancer [31, 65, 81, 96]. Because of being an inducer of pro-tumorigenic and pro-angiogenic phenotypes, therapeutic approaches targeting hyaluronidase are under intense investigation. So far partially sulfated hyaluronic acid polymers have been the only hyaluronidase inhibitors to be tested in an in vivo model. Benitez et al. showed delayed tumor growth in mice suffering of prostate cancer [7]. HA shed by hyaluronidase and measured in the plasma or urine is considered to be a marker of the integrity of the EG during sepsis, ischemia/reperfusion, and diabetes [26].

Important participants in the process of shedding of the EG are members of the ADAM family. The ADAM gene family is a member of a metallocproteinase superfamily, which includes a diverse group of multi-domain transmembrane and secreted proteins with a variety of biological functions. The main function of ADAM proteins is to regulate shedding of the extracellular domains of several proteins, such as tumor necrosis factor-α (TNFα) receptor, Notch, or transforming growth factor-α (TGFα) [14]. Specifically, ADAM17 has been shown to be involved in the degradation of the EG by shedding the ectodomain of syndecan-4 [94]. ADAM17 consists of three different domains: the prodomain, the catalytic domain, and the cytoplasmic domain. The catalytic domain is responsible for shedding and therefore it is the target structure for inhibition of ADAM17 [48]. ADAM17 has been implicated in a variety of diseases. As a TNFα-receptor-cleaving enzyme, ADAM17 has been shown to be upregulated in inflammatory diseases like rheumatoid arthritis or psoriasis [59, 92]. Because of its ability to shed growth factors, which are necessary for tumor growth and progression, ADAM17 has been reported to contribute to the development of a malignant phenotype [48]. Indeed, ADAM17 has been found to be overexpressed in breast and ovarian tumors [11, 116]. Involvement of ADAM17 in the setting of diabetes is most likely due to TNFα-activation through ADAM17 since treatment with an ADAM17 inhibitor improves insulin sensitivity [120]. In the context of the present discussion, ADAM17 activity is redox-dependent and oxidative stress enhances it [128]. Notably, renal microvascular endothelial cells isolated from SIRT1endo-/- mice exhibit a significant increase in basal and inducible generation of superoxide [73], thus potentially explaining the elevated activity of ADAM17 in these cells.

Having listed the sheddases with the known specific targeting of the EG, the question arises if inhibition of these enzymes could preserve the integrity of the EG. For instance, experimental studies revealed protection by antithrombin against shedding of the EG under ischaemic and inflammatory conditions [19]. The antithrombin molecule consists of a binding domain for heparin and heparan, which is responsible for its anti-inflammatory effects, besides inhibiting serine proteases [127]. In other words, antithrombin prevents degradation of the endothelial glyocalyx, because of a tight binding to heparan sulfate proteoglycans and, therefore, blocking access of sheddases. A different approach would be to inhibit the above mentioned sheddases directly. In a clinical study, inhibition of ADAM17 reduced the presence of the epidermal growth factor receptor ligand TGF-α, which is incriminated in renal fibrosis. Therefore, inhibition of ADAM17 has the potential to intervene in human renal diseases [82]. Furthermore, Hu et al. showed that intravenous injection of a MMP-9 inhibitor protects mice against lethal endotoxin shock [54]. Zeng et al. demonstrated protection of the EG through sphingosine-1-phosphate mediated inhibition of syndecan-1 shedding [132].

Summary

In summary, endothelial SIRT1-deficiency, a model of global endothelial dysfunction, leads to upregulation of syndecan-4
and release of its ectodomain, the loss of the EG through increased superoxide generation and induced NF-kB signaling. Furthermore syndecan-4, a major proteoglycan component of the EG and a binding partner of glycosaminoglycans comprising this structure are shed to a greater extent and its released ectodomain acts as a pro-fibrotic molecule, coordinating the inflammatory and pro-fibrogenic responses after applied damage to the endothelium and the consequent loss of the EG. The data and arguments presented herein provide a tentative outline of a potentially new target of SIRT1, endothelial glycocalyx, and emphasize the role of defective SIRT1 deacetylation in glycocalyx degradation.

Acknowledgements Open Access funding provided by Projekt DEAL.

Funding information Studies from authors laboratory were supported in part by Dr. Werner Jackstädt Foundation (to ML), the “IJJIN” Faculty Research Assistance Program of Yonsei University College of Medicine for 2013 (6-2013-0068) and Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning (NRF-2013R1A1A1010863) (to JS), and NIH grants HL144528, DK54602, DK052783 and DK45462 (to MSG).

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Abassi Z, Hamoud S, Hassan A, Khamaysi I, Nativ O, Heyman SN, Muhammad RS, Ilan N, Singh P, Hammond E, Zaza G, Lupo A, Onisto M, Bellin G, Masola V, Vlodavsky I, Gambardo G (2017) Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545. Oncotarget 8: 34191–34204. https://doi.org/10.18632/oncotarget.16573
2. Annecke T, Fischer J, Hartmann H, Tschoep J, Rehm M, Conzen P, Sommerhoff CP, Becker BF (2011) Shedding of the coronary endothelial glycocalyx: effects of hypoxia/reoxygenation vs ischaemia/reperfusion. Br J Anaesth 107:679–686. https://doi.org/10.1093/bja/aer269
3. Baker AB, Groothuis A, Jonas M, Ettensohn DS, Shazly T, Zeharia E, Vlodavsky I, Seifert P, Edelman ER (2009) Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res 104:380–387. https://doi.org/10.1161/CIRCRESAHA.108.180695
4. Becker BF (1993) Towards the physiological function of uric acid. Free Radic Biol Med 14:615–631. https://doi.org/10.1016/0891-5849(93)90143-i
5. Becker BF, Chappell D, Jacob M (2010) Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol 105:687–701. https://doi.org/10.1007/s00395-010-0118-z
6. Becker BF, Jacob M, Leipert S, Salmon AHJ, Chappell D (2015) Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol 80:389–402. https://doi.org/10.1111/bcp.12629
7. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, Lokeshwar VB (2011) Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res 71:4085–4095. https://doi.org/10.1158/0008-5472.CAN-10-4610
8. Boels MGS, Lee DH, van den Berg BM, Danc MJC, van der Vlag J, Rabelink TJJ (2013) The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome. Eur J Intern Med 24: 503–509. https://doi.org/10.1016/j.ejim.2012.12.016
9. Bombeli T, Schwartz BR, Harlan JM (1998) Adhesion of activated platelets to endothelial cells: evidence for a GPIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 187:329–339. https://doi.org/10.1084/jeum.187.3.329
10. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280–288. https://doi.org/10.1016/j.it.2004.03.008
11. Borrell-Pagès M, Rojo F, Albanell J, Baselga J, Arribas J (2003) TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22:1114–1124. https://doi.org/10.1093/emboj/cdg111
12. Bourguignon LYW, Xia W, Wong G (2009) Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates betacatenin signaling and NFkappab-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem 284:2657–2671. https://doi.org/10.1074/jbc.M806708200
13. Brasier AR (2006) The NF-kappab regulatory network. Cardiovasc Toxicol 6:111–130. https://doi.org/10.1085/ct.6:2:111
14. Brocker CN, Vasilou V, Nebert DW (2009) Evolutionary divergence and functions of the ADAM and ADAMTS gene families. Hum Genomics 4:43–55. https://doi.org/10.1186/1479-7364-4-1-43
15. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mosstolsvsky R, Cohen HY, Hu LS, Cheng H-L, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:2011–2015. https://doi.org/10.1126/science.1094637
16. Brunn GJ, Bungum MK, Johnson GB, Platt JL (2005) Conditional signaling by toll-like receptor 4. FASEB J 19:872–874. https://doi.org/10.1096/fj.04-3211fje
17. Chalkiadaki A, Guarente L (2015) The multifaceted functions of sirtuins in cancer. Nat Rev Cancer 15:608–624. https://doi.org/10.1038/nrc3985
18. Chappell D, Bruegger D, Potzel J, Jacob M, Brettnner F, Vogeser M, Conzen P, Becker BF, Rehm M (2014) Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx. Crit Care 18:538. https://doi.org/10.1186/s13054-014-0538-5
19. Chappell D, Jacob M, Hofmann-Kiefer K, Rehm M, Welsch U, Conzen P, Becker BF (2009) Antithrombin reduces shedding of
the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res 83:388–396. https://doi.org/10.1093/cvr/cvp097
20. Chen FE, Huang DB, Chen YQ, Ghosh G (1998) Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA. Nature 391:410–414. https://doi.org/10.1038/34956
21. Chen G, Wang D, Vikramadityan R, Yagyu H, Saxena U, Pillarsetti S, Goldberg IJ (2004) Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 43:4971–4977. https://doi.org/10.1021/bi0356552
22. Chen J, Xavier S, Moskowitz-Kassai E, Chen R, Lu CY, Sanduski K, Špes A, Turk B, Goligorsky MS (2012) Cathepsin cleavage of sirtuin 1 in endothelial progenitor cells mediates stress-induced premature senescence. Am J Pathol 180:973–983. https://doi.org/10.1016/j.ajpath.2011.11.033
23. Couchman JR (2003) Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 4:926–937. https://doi.org/10.1038/nrm1257
24. Couchman JR (2010) Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol 26:89–114. https://doi.org/10.1146/annurev-cellbio-100109-104126
25. Deckert T, Horovitz IM, Kofoid-Enevoldsen A, Kjellén L, Deckert M, Lykkeland C, Burcharth F (1991) Possible genetic defects in regulation of glycosaminoglycans in patients with diabetic nephropathy. Diabetes 40:764–770. https://doi.org/10.2337/diabetes.40.6.764
26. Dogné S, Flamion B (2020) Endothelial glycocalyx impairment in disease: focus on hyaluronan shedding. Am J Pathol 186:791–805. https://doi.org/10.1161/ajpath.119.11.016
27. Dragovich MA, Chester D, Fu BM, Wu C, Xu Y, Goligorsky MS, Zhang XF (2016) Mechanotransduction of the endothelial glycocalyx mediates nitric oxide production through activation of TRP channels. Am J Physiol, Cell Physiol 311:C846–C853. https://doi.org/10.1152/ajpcell.00288.2015
28. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez J, Zanoni I, Guy L, Wilcox L, van der Vlag J. (2014) The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrol Dial Transplant 30:4977–4988. https://doi.org/10.1093/ndt/gfu233
29. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M (1999) Syndecans-1 and -4 induce focal adhesion formation in vascular endothelial and smooth muscle cells. J Histochem Cytochem 47:783–791. https://doi.org/10.1177/002215549904700707
30. Eggli PS, Graber W (1995) Association of hyaluronan with rat vascular endothelial and smooth muscle cells. J Histochem Cytochem 43:689–697. https://doi.org/10.1177/43.7.608523
31. Eissa S, Swellam M, Shehata E, El-Khouly IM, El-Zayat T, El-Ahmady O (2010) Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol 183:493–498. https://doi.org/10.1016/j.juro.2009.10.024
32. Ellenbein A, Rhodes JM, Mellor J, Schwartz MA, Matsuda M, Simons M (2009) Suppression of RhoG activity is mediated by a syndecan 4-synctent-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway. J Cell Biol 186:75–83. https://doi.org/10.1083/jcb.200810179
33. Ellenbein A, Simons M (2013) Syndecan-4 signaling at a glance. J Cell Sci 126:3799–3804. https://doi.org/10.1242/jcs.124636
34. Endo K, Takino T, Miyamori H, Kinen H, Yoshizaki T, Furukawa M, Sato H (2003) Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278:40764–40770. https://doi.org/10.1074/jbc.M306736200
35. Eriksson AS, Spillmann D (2012) The mutual impact of syndecan-1 and its glycosaminoglycan chains—a multivariable puzzle. J Histochem Cytochem 60:936–942. https://doi.org/10.1369/0022155412460242
36. Fan J, Sun Y, Xia Y, Tarbell JM, Fu BM (2019) Endothelial surface glyocalyx (ESG) components and ultra-structure revealed by stochastic optical reconstruction microscopy (STORM). Bioheology 56:77–88. https://doi.org/10.3233/BIR-180204
37. Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM (2003) Heparan sulfate proteoglycan is a mechano-sensor on endothelial cells. Cire Res 93:e136–e142. https://doi.org/10.1161/01.RES.0000101744.47866.d5
38. Frye RA (1999) Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 260:273–279. https://doi.org/10.1016/j.bbrc.1999.0897
39. Fu BM, Tarbell JM (2013) Mechano-sensing and transduction by endothelial surface glyocalyx: composition, structure, and function. Wiley Interdiscip Rev Syst Biol Med 5:381–390. https://doi.org/10.1002/wsbm.1211
40. Gallo R, Kim C, Kokenyesi R, Adzick NS, Bernfield M (1996) Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. J Invest Dermatol 107:676–683. https://doi.org/10.1111/1523-1747.ep1256571
41. Garsen M, Benner M, Dijkman HB, van Kuppevelt TH, Li J-P, Rabelink TJ, Vlodavsky I, Berden JHM, Elkin M, van der Vlag J (2016) Heparanase is essential for the development of acute experimental glomerulonephritis. Am J Pathol 186:805–815. https://doi.org/10.1161/ajpath.115.12.008
42. Garsen M, Lenoir O, Rops ALWMM, Dijkman HB, Willemssen B, van Kuppevelt TH, Rabelink TJ, Berden JHM, Tharaux P-L, van der Vlag J (2016) Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glyocalyx. J Am Soc Nephrol 27:3545–3551. https://doi.org/10.16181/ASN.2015091070
43. Garsen M, Rops ALWMM, Rabelink TJ, Berden JHM, van der Vlag J (2014) The role of heparanase and the endothelial glyocalyx in the development of proteinuria. Nephrol Dial Transplant 29:49–55. https://doi.org/10.1093/ndt/gdt410
44. Garsen M, Lenoir O, Rops ALWMM, Dijkman HB, Willemssen B, van Kuppevelt TH, Rabelink TJ, Berden JHM, Tharaux P-L, van der Vlag J (2016) Endothelial heparanase induces proteinuria by heparanase-mediated disruption of the glomerular glyocalyx. J Am Soc Nephrol 27:3545–3551. https://doi.org/10.16181/ASN.2015091070
45. Goligorsky MS, Sun D (2020) Glyocalyx in Endotoxemia and Sepsis. Am J Pathol 190:791–798. https://doi.org/10.1016/j.ajpath.2019.06.017
46. Guo Z (2010) ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 45:146–169. https://doi.org/10.3109/10409231003628015
47. Gronski TJ, Martin RL, Kobayashi DK, Walsh BC, Holman MC, Huber M, Van Wart HE, Shapiro SD (1997) Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem 272:12189–12194. https://doi.org/10.1074/jbc.272.18.12189
48. Guarente L (2011) Franklin H. Epstein lecture: sirtuins, aging, and metabolism to DNA and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 260:273–279. https://doi.org/10.1016/j.bbrc.1999.0897
49. Hempel C, Pasini EM, Kurzthsals JAL (2016) Endothelial glyocalyx: shedding light on malaria pathogenesis. Trends Mol Med 22:453–457. https://doi.org/10.1016/j.trends.2016.04.004
glycocalyx in sepsis. J Pharmacol Exp Ther 361:115–121. https://doi.org/10.1124/jpet.116.239509

112. Sperandio M (2006) Selectins and glycosyltransferases in leukocyte rolling in vivo. FEBS J 273:4377–4389. https://doi.org/10.1111/j.1742-4658.2006.05473.x

113. Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87:1285–1342. https://doi.org/10.1152/physrev.00012.2007

114. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87:1285–1342. https://doi.org/10.1152/physrev.00012.2007

115. Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G (2000) Heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart. FEBS J 280:2228–2247. https://doi.org/10.1111/je.12161

116. Tanaoka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekata E, Nakano H (2005) Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloproteinase 17 expression in human ovarian cancer. Clin Cancer Res 11:4783–4792. https://doi.org/10.1158/1078-0432.CCR-04-1426

117. Taraboletti G, Dolo V (2002) Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 160:673–680. https://doi.org/10.1016/S0002-9440(10)64887-0

118. Teng YH-F, Aquino RS, Park PW (2012) Molecular functions of syndecan-1 in disease. Matrix Biol 31:3–16. https://doi.org/10.1016/j.mathbio.2011.10.001

119. Tkachenko E, Rhodes JM, Simons M (2005) Syndecans: new kids on the signaling block. Circ Res 96:488–500. https://doi.org/10.1161/01.RES.0000195708.71142.c8

120. Toyoshi N, Ura N, Higashita K, Murakami H, Shimamoto K (2002) Effect of TNF-alpha-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 39:578–580. https://doi.org/10.1161/01.hyp.0000032102.10392

121. Tomatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G (2012) The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol 22:557–566. https://doi.org/10.1016/j.tcb.2012.08.001

122. Tumova S, Woods A, Couchman JR (2000) Heparan sulfate chains from glypicans and syndecans bind the Hsp II domain of fibronectin similarly despite minor structural differences. J Biol Chem 275:9410–9417. https://doi.org/10.1074/jbc.275.13.9410

123. Vasko R, Xavier S, Chen J, Lin CHS, Ratliff B, Rabadi M, Maizel J, Tanokuchi R, Zhang F, Cao J, Goligorsky MS (2014) Endothelial sirtuin 1 deficiency perpetuates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. J Am Soc Nephrol 25:276–291. https://doi.org/10.1681/ASN.2013010069

124. Verma RP, Hansch C (2007) Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem 15:2223–2268. https://doi.org/10.1016/j.bmc.2007.01.011

125. Vuong TT, Reine TM, Sudworth A, Jensen SO, Kolset SO (2015) Syndecan-4 is a major syndecan in primary human endothelial cells in vitro, modulated by inflammatory stimuli and involved in wound healing. J Histochem Cytochem 63:280–292. https://doi.org/10.1369/00221551545568995

126. Wang G, Tiemeier GL, van den Berg BM, Rabelink TJ (2020) Endothelial glycocalyx hyaluronan: regulation and role in prevention of diabetic complications. Am J Pathol 190:781–790. https://doi.org/10.1016/j.ajpath.2019.07.022

127. Wang J, Wang Y, Jiang G, Zhao J, Tong C, Manihothy C, Li J, Rezaie AR (2013) Antithrombin is protective against myocardial ischemia and reperfusion injury. J Thromb Haemost 11:1020–1028. https://doi.org/10.1111/j.1742-4889.2011.07124.x

128. Wang Y, Herrera AH, Li Y, Belani KK, Walcheck B (2009) Regulation of mature ADAM17 by redox agents for L-selectin shedding. J Immunol 182:2449–2457. https://doi.org/10.4049/jimmunol.0802770

129. Wee YM, Go H, Choi MY, Jung HR, Cho YM, Kim YH, Han DJ, Shin S (2019) Tissue-resident natural killer cells exacerbate tubulointerstitial fibrosis by activating transglutaminase 2 and syndecan-4 in a model of aristolochic acid-induced nephropathy. BMB Rep 52:554–559

130. Xie J, Zhang X, Zhang L (2013) Negative regulation of inflammation by SIRT1. Pharmacol Res 67:60–67. https://doi.org/10.1016/j.phrs.2012.10.010

131. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Fyre RA, Mayo MW (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369–2380. https://doi.org/10.1038/sj.emboj.7600244

132. Zeng Y, Adamson RH, Curry F-RE, Tarbell JM (2014) Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart Circ Physiol 306:H363–H372. https://doi.org/10.1152/ajpheart.00876.2013

133. Zhang X, Sun D, Song JW, Zullo J, Lipphardt M, Conch-Gould L, Goligorsky MS (2018) Endothelial cell dysfunction and glycocalyx - a vicious circle. Matrix Biol 71–72:421–431. https://doi.org/10.1016/j.matbio.2018.01.026

134. Zullo JA, Fan J, Azar TT, Yen W, Zeng M, Chen J, Ratliff BB, Song J, Tarbell JM, Goligorsky MS, Fu BM (2016) Exocytosis of endothelial lysosome-related organelles hair-triggers a patchy loss of glycocalyx at the onset of sepsis. Am J Pathol 186:248–258. https://doi.org/10.1016/j.ajpath.2015.10.001